204 related articles for article (PubMed ID: 17288876)
21. Pazopanib. Kidney cancer: many risks, but is there a benefit for patients?
Prescrire Int; 2011 Mar; 20(114):64-6. PubMed ID: 21648224
[TBL] [Abstract][Full Text] [Related]
22. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
Heinrich MC; Joensuu H; Demetri GD; Corless CL; Apperley J; Fletcher JA; Soulieres D; Dirnhofer S; Harlow A; Town A; McKinley A; Supple SG; Seymour J; Di Scala L; van Oosterom A; Herrmann R; Nikolova Z; McArthur AG;
Clin Cancer Res; 2008 May; 14(9):2717-25. PubMed ID: 18451237
[TBL] [Abstract][Full Text] [Related]
23. [Tyrosine kinase inhibitor as adjuvant treatment of renal cell carcinoma: 1 versus 3].
Penel N
Bull Cancer; 2017 Sep; 104(9):705-706. PubMed ID: 28760312
[No Abstract] [Full Text] [Related]
24. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
Pietras K; Hanahan D
J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
[TBL] [Abstract][Full Text] [Related]
25. Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma.
Mukaihara K; Tanabe Y; Kubota D; Akaike K; Hayashi T; Mogushi K; Hosoya M; Sato S; Kobayashi E; Okubo T; Kim Y; Kohsaka S; Saito T; Kaneko K; Suehara Y
PLoS One; 2017; 12(9):e0185321. PubMed ID: 28945796
[TBL] [Abstract][Full Text] [Related]
26. Drug review: Pazopanib.
Miyamoto S; Kakutani S; Sato Y; Hanashi A; Kinoshita Y; Ishikawa A
Jpn J Clin Oncol; 2018 Jun; 48(6):503-513. PubMed ID: 29684209
[TBL] [Abstract][Full Text] [Related]
27. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Avramis IA; Laug WE; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
[TBL] [Abstract][Full Text] [Related]
28. Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma.
Bukowski RM
Expert Rev Anticancer Ther; 2010 May; 10(5):635-45. PubMed ID: 20469994
[TBL] [Abstract][Full Text] [Related]
29. A Case of Uterine Leiomyosarcoma with Long-Term Disease Control by Pazopanib.
Nagamata S; Ebina Y; Yamano Y; Miyamoto T; Nishijima M; Yamada H
Kobe J Med Sci; 2016 Jul; 62(2):E45-8. PubMed ID: 27578036
[TBL] [Abstract][Full Text] [Related]
30. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors.
Goh BC; Reddy NJ; Dandamudi UB; Laubscher KH; Peckham T; Hodge JP; Suttle AB; Arumugham T; Xu Y; Xu CF; Lager J; Dar MM; Lewis LD
Clin Pharmacol Ther; 2010 Nov; 88(5):652-9. PubMed ID: 20881954
[TBL] [Abstract][Full Text] [Related]
31. Increasing tumor uptake of anticancer drugs with imatinib.
Pietras K
Semin Oncol; 2004 Apr; 31(2 Suppl 6):18-23. PubMed ID: 15176000
[TBL] [Abstract][Full Text] [Related]
32. Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma.
Davids MS; Charlton A; Ng SS; Chong ML; Laubscher K; Dar M; Hodge J; Soong R; Goh BC
J Clin Oncol; 2009 Sep; 27(26):e97-100. PubMed ID: 19564526
[No Abstract] [Full Text] [Related]
33. Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells.
Li Y; Yang X; Su LJ; Flaig TW
Urology; 2011 Jul; 78(1):233.e7-13. PubMed ID: 21529900
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents.
Krystal GW
Drug Resist Updat; 2001 Feb; 4(1):16-21. PubMed ID: 11512148
[TBL] [Abstract][Full Text] [Related]
35. Ring a ring o'roses, a patient with Kaposi's? Pazopanib, pazopanib, it might go away. Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy.
Harris BHL; Walsh JL; Neciunaite R; Manders P; Cooper A; De Souza P
Clin Exp Dermatol; 2018 Mar; 43(2):234-236. PubMed ID: 29282751
[No Abstract] [Full Text] [Related]
36. Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High-Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial.
Maughan BL; Pal SK; Gill D; Boucher K; Martin C; Salgia M; Nussenzveig R; Liu T; Hawks JL; Batten J; Nachaegari G; Stephenson R; Lowrance W; Jones J; Dechet C; Agarwal N
Oncologist; 2018 Dec; 23(12):1413-e151. PubMed ID: 30575560
[TBL] [Abstract][Full Text] [Related]
37. Role of KIT and platelet-derived growth factor receptors as oncoproteins.
Fletcher JA
Semin Oncol; 2004 Apr; 31(2 Suppl 6):4-11. PubMed ID: 15175998
[TBL] [Abstract][Full Text] [Related]
38. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
Tortora G; Caputo R; Damiano V; Melisi D; Bianco R; Fontanini G; Veneziani BM; De Placido S; Bianco AR; Ciardiello F
Clin Cancer Res; 2003 Apr; 9(4):1566-72. PubMed ID: 12684433
[TBL] [Abstract][Full Text] [Related]
39. Good tolerability, long-term survival and easy management of side effects in a patient with metastatic renal cell carcinoma treated with pazopanib.
Frascaroli M; Di Cesare P
Tumori; 2014; 100(6):e301-4. PubMed ID: 25688516
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC; Seoane S; OcaƱa A; Pandiella A
Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]